You have a new cancer diagnosis that stops you in your tracks. You are sick, afraid, vulnerable and in pain when you come to the cancer center at Temple University Hospital. The first advocate you will meet on your cancer journey is your nurse navigator
In a finalist essay, Laurie Loe details why Vicki Dodson, B.S.N., RN, OCN, is an extraordinary healer and a great mentor.
Lynne O’Connor’s winning essay describes how Christine Santure, B.S.N., RN, OCN, is this year’s Extraordinary Healer winner by caring for the caregiver.
Supreme Court Justice Ruth Bader Ginsburg died after five bouts with cancer.
From new research finding an association with longer survival in patients with colorectal cancer and the amount of coffee they drink in a day to the historic wildfires in northern California damaging, and possibly destroying, a summer camp for pediatric patients with cancer and more, here’s what’s happening in the cancer landscape this week.
At a virtual event Sept. 17, CURE® also named Elizabeth Farrat, B.S.N., RN, CCRN-K, the winner of its first-ever Finest Hour Award for selfless achievements in care during the COVID-19 pandemic.
“This randomized clinical trial found that compared with the conventional anthracycline and docetaxel regimen, the paclitaxel-plus-carboplatin regimen may be an alternative adjuvant chemotherapy strategy for patients with operable TNBC,” the authors wrote.
Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.
Cancer makes your mind wander in many strange directions. If ever you wanted to know what an emotional rollercoaster really felt like, get on the cancer coaster and go for a ride.
The addition of immunotherapy to radiotherapy increased the overall survival of patients with cancer who developed brain metastases, according to new research.
Opioids are a common tool in treating cancer-related pain, but they are also at the center of a nationwide epidemic. One that researchers have found cancer patients are not as linked to as previously thought.
The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage test approved in this space.
Recent immunotherapy approvals for patients with metastatic melanoma has widened the treatment landscape, but new research shows that patients associated with positive sociodemographic factors are more likely to receive immunotherapy.
Younger and female patients with a variety of cancer types tend to have strong immune systems that naturally fight an array of cancer cells. The tumor cells the immune system doesn’t destroy are the most evasive, both to the immune system and medications that boost its activity, and this makes checkpoint inhibitor immunotherapy less effective in this population.
CURE® compiled a roundup of five recent reports patients with skin cancer may have missed.
The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.
On social media, CURE® recently asked its readers to share how they overcome the fear that comes with cancer. Here, we share some of their responses.
“With education and awareness to defeat the stigma, resources for those diagnosed, and innovative research toward cures, we can end colorectal cancer in our lifetime,” Michael Sapienza, CEO of Colorectal Cancer Alliance, said in a statement.
A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.
The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.
From the passing of famed Game of Thrones actress Dame Dianna Rigg after a lung cancer diagnosis to the recording of a confrontational call between a three-time cancer survivor and her senator’s staffer, here’s what’s happening in the cancer headlines this week.
Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.
Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.
When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.
Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.
The FDA based its decision on data from a phase 3 trial which showed that adding plinabulin to Neulasta significantly improved the rate of severe chemotherapy-induced neutropenia.
There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.
The Food and Drug Administration’s warning comes weeks after Genentech, the manufacturer of Tecentriq, issued a press release noting that the IMpassion131 trial failed to meet its primary endpoint of improving progression-free survival in patients with triple-negative breast cancer.
“Our hope is that this will enable us to reduce or eliminate late effects of treatment that persist into the survivorship years,” Dr. Peter Cole, of Rutgers Cancer Institute of New Jersey, said in a press release.
On social media, CURE® recently asked its readers to share the most surprising thing that’s changed in their life since receiving a cancer diagnosis. Here, we share some of their responses.
